On June 25, China Life Insurance rose 3.04% in regular trading, trading at 29.1 HKD/share, with turnover of HKD 609 million.

On the news front, the stock triggered an oversold recovery after falling below Goldman Sachs' neutral-rated 12-month target price of 28.5 HKD on June 24. The shares had corrected over 10% from their June 15 high of 31.02 HKD, pressured by regulatory penalties on subsidiaries involving fabrication of business documents and overdue claims settlements, as well as broader market pullback. Goldman Sachs' target price of 28.5 HKD, corresponding to 1.0x projected 2027 P/B, appeared to provide technical support and catalyzed buying interest.

Additionally, China Life reaffirmed its full-year target of double-digit new business value growth, while a stronger Q2 equity market is expected to improve investment performance. Within the Life and Health Insurance sector, the sector showed divergence, with Sunshine Insurance up 2.92%, China Taiping up 0.62%, NCI up 0.44%, while Ping An fell 0.85% and AIA declined 1.56%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)